Nicola Ashman

598 total citations · 1 hit paper
8 papers, 456 citations indexed

About

Nicola Ashman is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Nicola Ashman has authored 8 papers receiving a total of 456 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 5 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Molecular Biology. Recurrent topics in Nicola Ashman's work include HER2/EGFR in Cancer Research (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Chemical Synthesis and Analysis (2 papers). Nicola Ashman is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Chemical Synthesis and Analysis (2 papers). Nicola Ashman collaborates with scholars based in United Kingdom, Sweden and Singapore. Nicola Ashman's co-authors include David R. Spring, Jonathan D. Bargh, Stephen J. Walsh, Jason S. Carroll, Albert Isidro‐Llobet, Andrew J. Counsell, Abigail R. Hanby, Elaine Fowler, Jeremy S. Parker and Hikaru Seki and has published in prestigious journals such as Chemical Society Reviews, Chemical Communications and Chemical Science.

In The Last Decade

Nicola Ashman

7 papers receiving 442 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Site-selective modification strategies in antibody–drug conjugates

2020 315 citations Stephen J. Walsh, Jonathan D. Bargh et al. Chemical Society Reviews profile →

Peers

Countries citing papers authored by Nicola Ashman

Since Specialization

Citations

This map shows the geographic impact of Nicola Ashman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicola Ashman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicola Ashman more than expected).

Fields of papers citing papers by Nicola Ashman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicola Ashman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicola Ashman. The network helps show where Nicola Ashman may publish in the future.

Co-authorship network of co-authors of Nicola Ashman

This figure shows the co-authorship network connecting the top 25 collaborators of Nicola Ashman. A scholar is included among the top collaborators of Nicola Ashman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicola Ashman. Nicola Ashman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	MMP-cleavable linker platform for tumour-responsive homo- and heterobivalent antibody–drug conjugates 2025 ·Chemical Science ·Andrew J. Counsell, Stephen J. Walsh, Nicola Ashman, (unknown), (unknown), Thomas A. King, (unknown), Jason S. Carroll, David R. Spring	0
2	Tuneable thiol exchange linkers for traceless drug release applications in prodrugs and ADCs 2024 ·Chemical Communications ·Raoul Walther, (unknown), Nicola Ashman, Martin Welch, Jason S. Carroll, David R. Spring	3
3	Peroxide-cleavable linkers for antibody–drug conjugates 2023 ·Chemical Communications ·Nicola Ashman, Jonathan D. Bargh, Stephen J. Walsh, Ryan Greenwood, Arnaud Tiberghien, Jason S. Carroll, David R. Spring	17
4	Red-light modulated ortho -chloro azobenzene photoswitch for peptide stapling via aromatic substitution 2023 ·RSC Chemical Biology ·(unknown), (unknown), Nicola Ashman, Pamela J. E. Rowling, (unknown), Elaine Fowler, Laura S. Itzhaki, David R. Spring	11
5	Non-internalising antibody–drug conjugates 2022 ·Chemical Society Reviews ·Nicola Ashman, Jonathan D. Bargh, David R. Spring	67
6	Antibody dual-functionalisation enabled through a modular divinylpyrimidine disulfide rebridging strategy 2022 ·Chemical Communications ·Abigail R. Hanby, Stephen J. Walsh, Andrew J. Counsell, Nicola Ashman, Kim T. Mortensen, Jason S. Carroll, David R. Spring	12
7	A dual-enzyme cleavable linker for antibody–drug conjugates 2021 ·Chemical Communications ·Jonathan D. Bargh, Stephen J. Walsh, Nicola Ashman, Albert Isidro‐Llobet, Jason S. Carroll, David R. Spring	31
8	Site-selective modification strategies in antibody–drug conjugates breakdown → 2020 ·Chemical Society Reviews ·Stephen J. Walsh, Jonathan D. Bargh, (unknown), Abigail R. Hanby, Hikaru Seki, Andrew J. Counsell, (unknown), Elaine Fowler, Nicola Ashman, Yuri Takada, Albert Isidro‐Llobet, Jeremy S. Parker, Jason S. Carroll, David R. Spring	315

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact